Long pentraxin-3 inhibits FGF8b-dependent angiogenesis and growth of steroid hormone-regulated tumors

Molecular Cancer Therapeutics

Volumn 10, Issue 9, 2011, Pages 1600-1610

  Leali, Daria ^a,b   Alessi, Patrizia ^a   Coltrini, Daniela ^a   Ronca, Roberto ^a   Corsini, Michela ^a   Nardo, Giorgia ^c   Indraccolo, Stefano ^c   Presta, Marco ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b IRCCS MULTIMEDICA   (Italy)

^c VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTANOLONE; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 8B; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PENTRAXIN 3; STEROID HORMONE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CHO CELL; DRUG PROTEIN BINDING; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FEMALE; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; SURFACE PLASMON RESONANCE; TUMOR VASCULARIZATION;

ANDROGENS; ANGIOGENESIS INHIBITORS; ANIMALS; C-REACTIVE PROTEIN; CATTLE; CELL LINE; CELL PROLIFERATION; CHICK EMBRYO; CHO CELLS; CRICETINAE; FIBROBLAST GROWTH FACTOR 8; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, SCID; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN BINDING; SERUM AMYLOID P-COMPONENT;

EID: 80052761943     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-11-0286     Document Type: Article

References (46)

1. Presta M, Dell'Era P, Mitola S, Moroni E, Ronca R, Rusnati M. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 2005;16:159-78. (Pubitemid 40616114)
2. Mattila MM, Harkonen PL. Role of fibroblast growth factor 8 in growth and progression of hormonal cancer. Cytokine Growth Factor Rev 2007;18:257-66. (Pubitemid 46891289)
3. Song Z, Powell WC, Kasahara N, Van Bokhoven A, Miller GJ, Roy-Burman P. The effect of fibroblast growth factor 8, isoform b, on the biology of prostate carcinoma cells and their interaction with stromal cells. Cancer Res 2000;60:6730-6.
4. Hsieh AC, Small EJ, Ryan CJ. Androgen-response elements in hormone-refractory prostate cancer: implications for treatment development. Lancet Oncol 2007;8:933-9. (Pubitemid 47488068)
5. Schwertfeger KL. Fibroblast growth factors in development and cancer: insights from the mammary and prostate glands. Curr Drug Targets 2009;10:632-44.
6. Garlanda C, Bottazzi B, Bastone A, Mantovani A. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu Rev Immunol 2005;23:337-66. (Pubitemid 40563173)
7. Presta M, Camozzi M, Salvatori G, Rusnati M. Role of the soluble pattern recognition receptor PTX3 in vascular biology. J Cell Mol Med 2007;11:723-38. (Pubitemid 47313297)
8. Rusnati M, Camozzi M, Moroni E, Bottazzi B, Peri G, Indraccolo S, et al. Selective recognition of fibroblast growth factor-2 by the long pentraxin PTX3 inhibits angiogenesis. Blood 2004;104:92-9. (Pubitemid 38879843)
9. Camozzi M, Rusnati M, Bugatti A, Bottazzi B, Mantovani A, Bastone A, et al. Identification of an antiangiogenic FGF2-binding site in the N terminus of the soluble pattern recognition receptor PTX3. J Biol Chem 2006;281:22605-13.
10. Leali D, Alessi P, Coltrini D, Rusnati M, Zetta L, Presta M. Fibroblast growth factor-2 antagonist and antiangiogenic activity of long-pentraxin 3-derived synthetic peptides. Curr Pharm Des 2009;15:3577-89.
11. Mattila MM, Ruohola JK, Valve EM, Tasanen MJ, Seppanen JA, Harkonen PL. FGF-8b increases angiogenic capacity and tumor growth of androgen-regulated S115 breast cancer cells. Oncogene 2001;20:2791-804. (Pubitemid 32549836)
12. Isacchi A, Statuto M, Chiesa R, Bergonzoni L, Rusnati M, Sarmientos P, et al. A six-amino acid deletion in basic fibroblast growth factor dissociates its mitogenic activity from its plasminogen activator-inducing capacity. Proc Natl Acad Sci U S A 1991;88:2628-32. (Pubitemid 21916471)
13. Rivieccio V, Esposito A, Bellofiore P, Palladino P, Sassano M, Colombo M, et al. High-level expression and efficient purification of recombinant human long pentraxin PTX3 in Chinese hamster ovary cells. Protein Expr Purif 2007;51:49-58. (Pubitemid 44830113)
14. Bugatti A, Urbinati C, Ravelli C, De Clercq E, Liekens S, Rusnati M. Heparin-mimicking sulfonic acid polymers as multitarget inhibitors of HIV-1 Tat and gp120 proteins. Antimicrob Agents Chemother 2007;51:2337-45. (Pubitemid 47047308)
15. Esko JD. Genetic analysis of proteoglycan structure, function and metabolism. Curr Opin Cell Biol 1991;3:805-16. (Pubitemid 121006137)
16. Liekens S, Leali D, Neyts J, Esnouf R, Rusnati M, Dell'Era P, et al. Modulation of fibroblast growth factor-2 receptor binding, signaling, and mitogenic activity by heparin-mimicking polysulfonated compounds. Mol Pharmacol 1999;56:204-13. (Pubitemid 29309830)
17. Dong QG, Bernasconi S, Lostaglio S, De Calmanovici RW, Martin-Padura I, Breviario F, et al. A general strategy for isolation of endothelial cells from murine tissues. Characterization of two endothelial cell lines from the murine lung and subcutaneous sponge implants. Arterioscler Thromb Vasc Biol 1997;17:1599-604. (Pubitemid 27387783)
18. Leppa S, Harkonen P, Jalkanen M. Steroid-induced epithelial-fibroblastic conversion associated with syndecan suppression in S115 mouse mammary tumor cells. Cell Regul 1991;2:1-11.
19. Presta M, Maier JA, Rusnati M, Ragnotti G. Basic fibroblast growth factor: production, mitogenic response, and post-receptor signal transduction in cultured normal and transformed fetal bovine aortic endothelial cells. J Cell Physiol 1989;141:517-26. (Pubitemid 20014299)
20. Borgenstrom M, Jalkanen M, Salmivirta M. Sulfated derivatives of Escherichia coli K5 polysaccharides as modulators of fibroblast growth factor signaling. J Biol Chem 2003;278:49882-9. (Pubitemid 37548823)
21. Noguchi S, Uchida N, Sato B, Koyama H, Matsumoto K. Growth control of androgen-dependent Shionogi carcinoma cells by growth factor(s) produced from androgen-independent Shionogi carcinoma cells in a paracrine mechanism. J Steroid Biochem 1989;32:479-83. (Pubitemid 19135498)
22. Tanaka A, Matsumoto K, Nishizawa Y, Lu J, Yamanishi H, Maeyama M, et al. Growth stimulation by androgens, glucocorticoids or fibroblast growth factors and the blocking of the stimulated growth by antibody against basic fibroblast growth factor in protein-free culture of Shionogi carcinoma 115 cells. J Steroid Biochem Mol Biol 1990;37:23-9. (Pubitemid 20385632)
23. Leali D, Belleri M, Urbinati C, Coltrini D, Oreste P, Zoppetti G, et al. Fibroblast growth factor-2 antagonist activity and angiostatic capacity of sulfated Escherichia coli K5 polysaccharide derivatives. J Biol Chem 2001;276:37900-8.
24. Morgenstern JP, Land H. Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res 1990;18:3587-96.
25. Knoll A, Schmidt S, Chapman M, Wiley D, Bulgrin J, Blank J, et al. A comparison of two controlled-release delivery systems for the delivery of amiloride to control angiogenesis. Microvasc Res 1999;58:1-9. (Pubitemid 29390220)
26. Ribatti D, Gualandris A, Bastaki M, Vacca A, Iurlaro M, Roncali L, et al. New model for the study of angiogenesis and antiangiogenesis in the chick embryo chorioallantoic membrane: the gelatin sponge/chorioallantoic membrane assay. J Vasc Res 1997;34:455-63. (Pubitemid 28008032)
27. Euhus DM, Hudd C, LaRegina MC, Johnson FE. Tumor measurement in the nude mouse. J Surg Oncol 1986;31:229-34. (Pubitemid 16104025)
28. Tomayko MM, Reynolds CP. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol 1989;24:148-54. (Pubitemid 19163397)
29. Mohammadi M, Olsen SK, Ibrahimi OA. Structural basis for fibroblast growth factor receptor activation. Cytokine Growth Factor Rev 2005;16:107-37. (Pubitemid 40616111)
30. Olsen SK, Li JY, Bromleigh C, Eliseenkova AV, Ibrahimi OA, Lao Z, et al. Structural basis by which alternative splicing modulates the organizer activity of FGF8 in the brain. Genes Dev 2006;20:185-98. (Pubitemid 43112937)
31. Schlessinger J, Plotnikov AN, Ibrahimi OA, Eliseenkova AV, Yeh BK, Yayon A, et al. Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization. Mol Cell 2000;6:743-50.
32. Ruohola JK, Valve EM, Vainikka S, Alitalo K, Harkonen PL. Androgen and fibroblast growth factor (FGF) regulation of FGF receptors in S115 mouse mammary tumor cells. Endocrinology 1995;136:2179-88.
33. Ruohola JK, Valve EM, Karkkainen MJ, Joukov V, Alitalo K, Harkonen PL. Vascular endothelial growth factors are differentially regulated by steroid hormones and antiestrogens in breast cancer cells. Mol Cell Endocrinol 1999;149:29-40. (Pubitemid 29236221)
34. Dorkin TJ, Robinson MC, Marsh C, Bjartell A, Neal DE, Leung HY. FGF8 over-expression in prostate cancer is associated with decreased patient survival and persists in androgen independent disease. Oncogene 1999;18:2755-61. (Pubitemid 29237664)
35. Maruyama-Takahashi K, Shimada N, Imada T, Maekawa-Tokuda Y, Ishii T, Ouchi J, et al. A neutralizing anti-fibroblast growth factor (FGF) 8 monoclonal antibody shows anti-tumor activity against FGF8b-expressing LNCaP xenografts in androgen-dependent and -independent conditions. Prostate 2008;68:640-50. (Pubitemid 351614642)
36. Udayakumar TS, Bair EL, Nagle RB, Bowden GT. Pharmacological inhibition of FGF receptor signaling inhibits LNCaP prostate tumor growth, promatrilysin, and PSA expression. Mol Carcinog 2003;38:70-7. (Pubitemid 37255142)
37. Koziczak M, Holbro T, Hynes NE. Blocking of FGFR signaling inhibits breast cancer cell proliferation through downregulation of D-type cyclins. Oncogene 2004;23:3501-8. (Pubitemid 38658416)
38. Reis-Filho JS, Simpson PT, Turner NC, Lambros MB, Jones C, Mackay A, et al. FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas. Clin Cancer Res 2006;12:6652-62. (Pubitemid 44876833)
39. Gowardhan B, Douglas DA, Mathers ME, McKie AB, McCracken SR, Robson CN, et al. Evaluation of the fibroblast growth factor system as a potential target for therapy in human prostate cancer. Br J Cancer 2005;92:320-7. (Pubitemid 40343148)
40. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 2004;6:1-6. (Pubitemid 38391943)
41. Garlanda C, Hirsch E, Bozza S, Salustri A, De Acetis M, Nota R, et al. Non-redundant role of the long pentraxin PTX3 in anti-fungal innate immune response. Nature 2002;420:182-6. (Pubitemid 35340122)
42. Leali D, Bianchi R, Bugatti A, Nicoli S, Mitola S, Ragona L, et al. Fibroblast growth factor 2-antagonist activity of a long-pentraxin 3-derived anti-angiogenic pentapeptide. J Cell Mol Med 2010;14:2109-21.
43. Alessi P, Leali D, Camozzi M, Cantelmo A, Albini A, Presta M. Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist. Eur Cytokine Netw 2009;20:225-34.
44. Colombo G, Margosio B, Ragona L, Neves M, Bonifacio S, Annis DS, et al. Non-peptidic thrombospondin-1 mimics as fibroblast growth factor-2 inhibitors: an integrated strategy for the development of new antiangiogenic compounds. J Biol Chem 2010;285:8733-42.
45. Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005;8:299-309. (Pubitemid 41443415)
46. Brower V. How well do angiogenesis inhibitors work? Biomarkers of response prove elusive. J Natl Cancer Inst 2009;101:846-7.